Publication | Open Access

First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status

First-line PembrolizumabMedicinePathologyImmune Checkpoint InhibitorPoor Performance StatusCancer TreatmentOncologyRadiation OncologyLung Cancer